DK3570834T3 - Bicyclic inhibitors of histone deacetylase - Google Patents

Bicyclic inhibitors of histone deacetylase Download PDF

Info

Publication number
DK3570834T3
DK3570834T3 DK18702839.4T DK18702839T DK3570834T3 DK 3570834 T3 DK3570834 T3 DK 3570834T3 DK 18702839 T DK18702839 T DK 18702839T DK 3570834 T3 DK3570834 T3 DK 3570834T3
Authority
DK
Denmark
Prior art keywords
histone deacetylase
bicyclic inhibitors
bicyclic
inhibitors
deacetylase
Prior art date
Application number
DK18702839.4T
Other languages
English (en)
Inventor
Nathan Oliver Fuller
John A Lowe Iii
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of DK3570834T3 publication Critical patent/DK3570834T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18702839.4T 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase DK3570834T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445022P 2017-01-11 2017-01-11
US201762555298P 2017-09-07 2017-09-07
PCT/US2018/013260 WO2018132531A1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
DK3570834T3 true DK3570834T3 (en) 2022-02-28

Family

ID=61074595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18702839.4T DK3570834T3 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase

Country Status (26)

Country Link
US (7) US10793567B2 (da)
EP (2) EP3570834B1 (da)
JP (1) JP6756925B2 (da)
KR (1) KR102526032B1 (da)
CN (1) CN110290789B (da)
AU (1) AU2018207402B2 (da)
BR (1) BR112019014235A2 (da)
CA (1) CA3049443A1 (da)
CY (1) CY1125287T1 (da)
DK (1) DK3570834T3 (da)
ES (2) ES2875562T3 (da)
HR (1) HRP20220223T1 (da)
HU (1) HUE057849T2 (da)
IL (1) IL267953B2 (da)
LT (1) LT3570834T (da)
MA (1) MA47305A (da)
MD (1) MD3570834T2 (da)
MX (1) MX2019008302A (da)
PL (1) PL3570834T3 (da)
PT (1) PT3570834T (da)
RS (1) RS62959B1 (da)
SG (1) SG11201906164RA (da)
SI (1) SI3570834T1 (da)
TW (1) TWI770104B (da)
WO (2) WO2018132531A1 (da)
ZA (1) ZA201904459B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
PL3570834T3 (pl) 2017-01-11 2022-05-23 Alkermes, Inc. Bicykliczne inhibitory deacetylazy histonowej
RS63343B1 (sr) * 2017-08-07 2022-07-29 Alkermes Inc Biciklični inhibitori histonske deacetilaze
EP3982968A4 (en) * 2019-06-13 2023-07-05 Dana-Farber Cancer Institute, Inc. DEVELOPMENT OF CATALYTIC HDAC3 INHIBITORS AND THEIR USES
EP4003958A1 (en) * 2019-07-23 2022-06-01 Alkermes, Inc. Synthesis of bicyclic inhibitors of histone deacetylase
CN110734924B (zh) * 2019-10-25 2020-10-23 山东大学第二医院 一种抑郁症检测、治疗和预后靶点及应用

Family Cites Families (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
EA000304B1 (ru) 1995-02-02 1999-04-29 Смитклайн Бичам Плс Производные индола как антагонисты рецептора 5-ht
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
CA2249607A1 (en) 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
JPH1149676A (ja) 1997-07-31 1999-02-23 Geron Corp ピリジン系テロメラーゼ阻害剤
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
KR20010110667A (ko) 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
HUP0302475A2 (hu) 2000-09-06 2003-11-28 Ortho-Mcneil Pharmaceutical, Inc. Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával
WO2002026708A1 (fr) 2000-09-27 2002-04-04 Toray Industries, Inc. Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
NZ526336A (en) 2000-12-07 2004-11-26 Cv Therapeutics Inc Substituted 1, 3,5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
ES2292830T3 (es) 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004000820A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP2080757A1 (en) 2003-07-24 2009-07-22 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
TWI287567B (en) 2003-07-30 2007-10-01 Chi Mei Optoelectronics Corp Light-emitting element and iridium complex
EP1651638A1 (en) 2003-08-08 2006-05-03 Janssen Pharmaceutica N.V. Pyridyl piperazinyl ureas
WO2005016862A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
RU2006138036A (ru) 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
BRPI0509298A (pt) 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
ES2325865T3 (es) 2004-07-26 2009-09-22 Eli Lilly And Company Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
US20090018145A1 (en) 2004-10-19 2009-01-15 Compass Pharmaceuticals Llc Compositions and their use as anti-tumor agents
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
CA2588389A1 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
BRPI0519181A2 (pt) 2004-12-22 2008-12-30 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente
US20060173019A1 (en) 2005-01-14 2006-08-03 Solomon Ungashe Heteroaryl sulfonamides and CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP1683796A1 (en) 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7682404B2 (en) 2005-05-13 2010-03-23 Ciba Specialty Chemicals Corporation Coloring keratin fibers with metal complexes
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
CN101208088A (zh) 2005-06-02 2008-06-25 拜尔农作物科学股份公司 苯基烷基取代的杂芳基衍生物
CA2610884A1 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
AR053901A1 (es) 2005-06-20 2007-05-23 Astrazeneca Ab Formas fisicas de oxabispidinas n,n'- disustituidas
DE602006011752D1 (de) 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
NZ568666A (en) 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
CA2633425A1 (en) 2005-12-23 2007-06-28 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
WO2007087130A2 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Hydroxyalkylarylamide derivatives
US20090012075A1 (en) 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
JP2007283748A (ja) 2006-03-23 2007-11-01 Fujifilm Corp 光記録媒体および可視情報記録方法
HUE042037T2 (hu) 2006-03-27 2019-06-28 Univ California Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2007125984A1 (ja) 2006-04-28 2007-11-08 Nihon Nohyaku Co., Ltd. イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
US20090118336A1 (en) 2006-05-03 2009-05-07 Laurent David Pyrazole derivatives and their use as pi3k inhibitors
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2007138072A2 (en) 2006-05-31 2007-12-06 Galapagos N.V. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
US20100022547A1 (en) 2006-06-02 2010-01-28 Brandeis University Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
TW200817375A (en) 2006-07-21 2008-04-16 Irm Llc Compounds and compositions as ITPKB inhibitors
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CA2658887C (en) 2006-07-28 2016-08-23 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20080076813A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
MX2009002842A (es) 2006-09-18 2009-05-27 Vertex Pharma Inhibidores heterociclicos de c-met y usos de los mismos.
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
US20080145816A1 (en) 2006-12-15 2008-06-19 Hershey Adrienne A Yankauer suction device
SG177911A1 (en) 2006-12-21 2012-02-28 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179068A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP2008179067A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
CA2702647C (en) 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
EP2146983A1 (en) 2007-04-20 2010-01-27 Biolipox AB Pyrazoles useful in the treatment of inflammation
WO2008139152A1 (en) 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
MY154462A (en) 2007-06-05 2015-06-30 Sanofi Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CN101808518A (zh) 2007-06-27 2010-08-18 默沙东公司 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物
UY31281A1 (es) 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
US8354383B2 (en) 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
EP2197552B1 (en) * 2007-09-19 2012-11-21 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
NZ584279A (en) 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
WO2009052319A1 (en) 2007-10-16 2009-04-23 Northeastern University Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity
US20090156825A1 (en) 2007-11-26 2009-06-18 Heidebrecht Jr Richard W Fluorescent compounds that bind to histone deacetylase
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
AU2009257635A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
EA201100049A1 (ru) 2008-06-27 2011-08-30 Новартис Аг Органические соединения
CA2730511C (en) 2008-07-11 2013-06-11 Robert Epple 4-phenoxymethylpiperidines as modulators of gpr119 activity
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
EP2548618A3 (en) 2008-07-15 2013-02-27 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
CN102227421A (zh) 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
EP2417125B1 (en) 2009-03-27 2015-09-09 Nerviano Medical Sciences S.r.l. N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
JP2012522748A (ja) 2009-04-01 2012-09-27 ノバルティス アーゲー ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体
CA2758289A1 (en) 2009-05-07 2010-11-11 Gruenenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
NZ596863A (en) 2009-06-08 2014-02-28 Gilead Sciences Inc Alkanoylamino benzamide aniline hdac inhibitor compounds
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2521724B1 (en) 2009-12-11 2016-11-23 Nono Inc. Agents and methods for treating ischemic and other diseases
EP3000482B1 (en) 2009-12-16 2021-04-21 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
EP2550260A1 (en) 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
JP5499160B2 (ja) 2010-04-06 2014-05-21 日本曹達株式会社 含窒素複素環化合物及びその製造方法
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
MX2012015252A (es) 2010-06-30 2013-05-30 Ironwood Pharmaceuticals Inc Estimuladores de sgc.
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US20140018538A1 (en) 2010-08-20 2014-01-16 President And Fellows Of Harvard College High-valent palladium fluoride complexes and uses thereof
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
WO2012074050A1 (ja) 2010-12-01 2012-06-07 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板、液晶表示装置、及び化合物
EP2654796A1 (en) 2010-12-21 2013-10-30 Koninklijke Philips N.V. Agents for clearing biomolecules from circulation
JP2014500303A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US20130303507A1 (en) 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
EP2681205B1 (en) 2011-03-03 2016-11-16 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
KR20140051846A (ko) 2011-03-18 2014-05-02 루핀 리미티드 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9421274B2 (en) 2011-05-16 2016-08-23 Koninklijke Philips N.V. Bio-orthogonal drug activation
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
AR087302A1 (es) 2011-07-26 2014-03-12 Gruenenthal Gmbh Derivados aza heterociclicos sustituidos
PE20140836A1 (es) 2011-07-26 2014-08-03 Gruenenthal Chemie Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013024004A1 (en) 2011-08-12 2013-02-21 Basf Se N-thio-anthranilamide compounds and their use as pesticides
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
JP2014527973A (ja) 2011-09-23 2014-10-23 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する作用剤としての４−置換１−フェニルピラゾール−３−カルボン酸誘導体の使用
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2867760C (en) 2012-04-04 2021-10-05 Rigel Pharmaceuticals, Inc. Indolizinyl derivatives as protein kinase c inhibitors and uses thereof
WO2013152727A1 (en) 2012-04-12 2013-10-17 The University Of Hong Kong Platinum(ii) complexes for oled applications
WO2013163404A1 (en) 2012-04-27 2013-10-31 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
EP2857396B1 (en) 2012-05-31 2018-11-21 Sumitomo Chemical Co., Ltd Fused heterocyclic compounds for pest control
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA2874953A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2013188813A2 (en) 2012-06-15 2013-12-19 The Regents Of The University Of California Novel therapeutics for brain cancer
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9682970B2 (en) 2012-06-29 2017-06-20 Biotium, Inc. Fluorescent compounds and uses thereof
RU2696278C2 (ru) 2012-07-18 2019-08-01 Юниверсити Оф Нотр Дам Дю Лак 5,5-гетероароматические противоинфекционные соединения
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
MX2015004151A (es) 2012-10-05 2015-07-06 Rigel Pharmaceuticals Inc Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
CN104994857A (zh) 2012-10-11 2015-10-21 格吕伦塔尔有限公司 Tspo介导的疾病和/或障碍的治疗和/或预防
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US20150292045A1 (en) 2012-11-09 2015-10-15 Indiana University Research And Technology Corporation Alternative uses for hbv assembly effectors
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
EP2922574B1 (en) 2012-11-22 2023-05-17 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081301A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
JP6357167B2 (ja) 2012-12-04 2018-07-11 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびそれらの用途
CN103864754B (zh) 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
US9890127B2 (en) 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CN105228997B (zh) 2013-03-15 2018-03-27 Epizyme股份有限公司 Carm1抑制剂及其用途
EP2968339A4 (en) 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
BR112015024109A2 (pt) 2013-03-20 2017-07-18 Hoffmann La Roche derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104163791B (zh) 2013-05-20 2017-05-03 湖南化工研究院 N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用
CN104163792B (zh) 2013-05-20 2017-04-12 湖南化工研究院 N‑吡啶酰胺类化合物及其制备方法与应用
WO2014190199A1 (en) 2013-05-24 2014-11-27 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
CN105682665A (zh) 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
KR102349659B1 (ko) 2013-06-10 2022-01-11 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 개질된 방출 스펙트럼을 갖는 인광성 네자리 금속 착물
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
SG11201601066VA (en) 2013-09-06 2016-03-30 Inception 2 Inc Triazolone compounds and uses thereof
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
EP3055287B1 (en) 2013-10-08 2019-11-06 Lu, Qing-Bin Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
WO2015061247A2 (en) 2013-10-21 2015-04-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
WO2015077246A1 (en) 2013-11-19 2015-05-28 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
CN103601718A (zh) 2013-12-05 2014-02-26 江西天人生态股份有限公司 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
CN103804312B (zh) 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015142903A2 (en) 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
GB201405002D0 (en) 2014-03-20 2014-05-07 Isis Innovation Fluorination method
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
WO2015157057A1 (en) 2014-04-09 2015-10-15 Lumiphore, Inc Macrocycles
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016018795A1 (en) 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
CN107124882A (zh) 2014-08-04 2017-09-01 基础应用医学研究基金会 用于认知改善的新型化合物
CA2958193C (en) 2014-08-18 2024-02-27 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
CA2963681A1 (en) 2014-10-08 2016-04-14 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2016100711A1 (en) 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
EP3259264B1 (en) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
CN106083823A (zh) 2015-04-30 2016-11-09 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
WO2017027984A1 (en) 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
WO2017046133A1 (en) 2015-09-14 2017-03-23 Universiteit Antwerpen Process for the catalytic directed cleavage of amide-containing compounds
CA3003930A1 (en) 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
BR112018016724B1 (pt) 2016-02-23 2024-02-20 Taiho Pharmaceutical Co., Ltd Composto de pirimidina condensado ou sal do mesmo, seus usos, inibidor de ret, agente antitumor e composição farmacêutica
WO2017156265A1 (en) 2016-03-09 2017-09-14 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10385031B2 (en) 2016-11-23 2019-08-20 Regenacy Pharmaceuticals, Llc Substituted piperazines as selective HDAC1,2 inhibitors
PL3570834T3 (pl) 2017-01-11 2022-05-23 Alkermes, Inc. Bicykliczne inhibitory deacetylazy histonowej
CN106946890A (zh) 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
RS63343B1 (sr) 2017-08-07 2022-07-29 Alkermes Inc Biciklični inhibitori histonske deacetilaze
MX2021000469A (es) 2018-07-13 2021-06-23 Alkermes Inc Inhibidores biciclicos de las histona desacetilasas.
JP7414820B2 (ja) 2018-07-13 2024-01-16 アルカーメス，インコーポレイテッド ヒストンデアセチラーゼの阻害剤

Also Published As

Publication number Publication date
SG11201906164RA (en) 2019-08-27
US9951069B1 (en) 2018-04-24
US20210122748A1 (en) 2021-04-29
LT3570834T (lt) 2022-03-10
JP2020504156A (ja) 2020-02-06
AU2018207402A1 (en) 2019-07-18
EP3568135A1 (en) 2019-11-20
PL3570834T3 (pl) 2022-05-23
PT3570834T (pt) 2022-03-01
CA3049443A1 (en) 2018-07-19
KR20190104389A (ko) 2019-09-09
SI3570834T1 (sl) 2022-05-31
BR112019014235A2 (pt) 2020-03-17
ZA201904459B (en) 2021-02-24
MA47305A (fr) 2019-11-27
WO2018132531A1 (en) 2018-07-19
CN110290789A (zh) 2019-09-27
CN110290789B (zh) 2022-10-18
IL267953A (en) 2019-09-26
TW201831183A (zh) 2018-09-01
IL267953B (en) 2022-10-01
TWI770104B (zh) 2022-07-11
US10793567B2 (en) 2020-10-06
MD3570834T2 (ro) 2022-04-30
AU2018207402B2 (en) 2023-09-28
US20210053964A1 (en) 2021-02-25
ES2909086T3 (es) 2022-05-05
US10696673B2 (en) 2020-06-30
US20220340560A1 (en) 2022-10-27
EP3570834B1 (en) 2021-12-22
US11987580B2 (en) 2024-05-21
KR102526032B1 (ko) 2023-04-25
US20190337953A1 (en) 2019-11-07
US11286256B2 (en) 2022-03-29
US10519149B2 (en) 2019-12-31
EP3568135B1 (en) 2021-04-07
HRP20220223T1 (hr) 2022-04-29
EP3570834A1 (en) 2019-11-27
HUE057849T2 (hu) 2022-06-28
MX2019008302A (es) 2019-12-02
US20200148678A1 (en) 2020-05-14
RS62959B1 (sr) 2022-03-31
ES2875562T3 (es) 2021-11-10
CY1125287T1 (el) 2023-06-09
IL267953B2 (en) 2023-02-01
US11225479B2 (en) 2022-01-18
WO2018132533A1 (en) 2018-07-19
JP6756925B2 (ja) 2020-09-16
US20180215759A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
SI3319959T1 (sl) Hetero-halo inhibitorji histonske deacetilaze
HK1252489A1 (zh) 組蛋白去乙酰化酶抑制劑及其組合物和使用方法
IL267953A (en) Bicyclic histone deacetylase inhibitors
IL263360A (en) Combinations comprising histone deacetylase inhibitors
ZA201805066B (en) Use of histone deacetylase inhibitors for enhancing immunotherapies
IL249339A0 (en) Histone deacetylase inhibitors and compositions and methods of using them
IL272479B1 (en) Bicyclic histone deacetylase inhibitors
IL279920A (en) Bicyclic histone deacetylase inhibitors
IL267465A (en) Histone deacetylase inhibitors
HK1252487A1 (zh) 組蛋白去乙酰化酶抑制劑及其組合物和使用方法
IL279940A (en) Histone deacetylase inhibitors
IL256438B (en) Histone deacetylase inhibitors
GB201803361D0 (en) Histone deacetylase inhibitors